Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
Go back to Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma| Agilent Technologies Inc (NYSE: A) | Delayed: 128.06 +1.57 (1.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $126.49 | 52 Week High | $48.63 | |||
| Open | $127.28 | 52 Week Low | $34.15 | |||
| Day High | $128.68 | P/E | 59.29 | |||
| Day Low | $126.58 | EPS | $2.16 | |||
| Volume | 79,901 | |||||
